Partial response or better at six months is prognostic of superior progression‐free survival in Waldenström macroglobulinaemia patients treated with ibrutinib-Reference-Cited by-同舟云学术

Partial response or better at six months is prognostic of superior progression‐free survival in Waldenström macroglobulinaemia patients treated with ibrutinib

Published:2020-11-18 Issue:3 Volume:192 Page:542-550
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Castillo Jorge J.¹²^ORCID,Abeykoon Jithma P.³^ORCID,Gustine Joshua N.¹⁴,Zanwar Saurabh³^ORCID,Mein Kirsten¹,Flynn Catherine A.¹,Demos Maria G.¹,Guerrera Maria L.¹,Kofides Amanda¹,Liu Xia¹,Munshi Manit¹,Tsakmaklis Nickolas¹,King Rebecca⁵,Yang Guang¹,Hunter Zachary R.¹^ORCID,Advani Ranjana H.⁶^ORCID,Palomba Maria Lia⁷^ORCID,Ansell Stephen M.³,Gertz Morie A.³^ORCID,Kapoor Prashant³^ORCID,Treon Steven P.¹²^ORCID

Affiliation:

1. Bing Center for Waldenström Macroglobulinemia Dana‐Farber Cancer Institute Boston MAUSA

2. Department of Medicine Harvard Medical School Boston MAUSA

3. Division of Hematology Department of Medicine Mayo Clinic Rochester MNUSA

4. Department of Medicine Boston University Medical School Boston MAUSA

5. Department of Laboratory Medicine and Pathology Mayo Clinic Rochester MNUSA

6. Stanford Cancer Institute Stanford University Stanford CAUSA

7. Department of Medicine Lymphoma Service Memorial Sloan Kettering Cancer Center New York NY USA

Publisher

Wiley

Subject

Hematology